Zoetis (NYSE:ZTS) issued its earnings results on Thursday. The company reported $0.69 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.03, Bloomberg Earnings reports. The company had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.40 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. Zoetis’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.47 EPS. Zoetis updated its FY18 guidance to $2.96-3.10 EPS.

Zoetis (NYSE ZTS) opened at $78.71 on Thursday. The firm has a market cap of $35,688.99, a PE ratio of 39.19, a price-to-earnings-growth ratio of 1.62 and a beta of 1.07. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45. Zoetis has a fifty-two week low of $52.00 and a fifty-two week high of $80.60.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be issued a $0.126 dividend. The ex-dividend date is Thursday, April 19th. This represents a $0.50 annualized dividend and a yield of 0.64%. Zoetis’s dividend payout ratio is currently 26.32%.

ZTS has been the topic of a number of research analyst reports. BMO Capital Markets reaffirmed a “hold” rating and issued a $65.00 target price on shares of Zoetis in a report on Thursday, November 2nd. Cowen set a $80.00 target price on shares of Zoetis and gave the company a “buy” rating in a report on Friday, November 17th. Morgan Stanley raised shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 target price on the stock in a report on Wednesday, November 29th. UBS Group reaffirmed a “neutral” rating on shares of Zoetis in a report on Friday, November 24th. Finally, Citigroup raised shares of Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 target price on the stock in a report on Thursday, January 4th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the stock. Zoetis presently has a consensus rating of “Buy” and an average target price of $73.72.

Institutional investors have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd increased its holdings in shares of Zoetis by 7.3% during the second quarter. Dynamic Technology Lab Private Ltd now owns 5,901 shares of the company’s stock worth $368,000 after purchasing an additional 401 shares during the period. Robecosam AG increased its holdings in shares of Zoetis by 4.6% during the fourth quarter. Robecosam AG now owns 15,346 shares of the company’s stock worth $1,111,000 after purchasing an additional 679 shares during the period. Daiwa Securities Group Inc. increased its holdings in shares of Zoetis by 4.3% during the fourth quarter. Daiwa Securities Group Inc. now owns 16,828 shares of the company’s stock worth $1,212,000 after purchasing an additional 697 shares during the period. Sandy Spring Bank increased its holdings in shares of Zoetis by 2.3% during the fourth quarter. Sandy Spring Bank now owns 31,018 shares of the company’s stock worth $2,235,000 after purchasing an additional 708 shares during the period. Finally, Penserra Capital Management LLC increased its holdings in shares of Zoetis by 18.6% during the fourth quarter. Penserra Capital Management LLC now owns 4,550 shares of the company’s stock worth $327,000 after purchasing an additional 715 shares during the period. 93.72% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Zoetis (ZTS) Releases Earnings Results, Beats Expectations By $0.03 EPS” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2018/02/15/zoetis-zts-releases-earnings-results-beats-expectations-by-0-03-eps.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Earnings History for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.